Total: $307.5M


Company

Location

Date

Amt. (M)

Details


Advanced Accelerator Applications S.A.

Saint Genis Pouilly, France

7/25

€40 ($57.4)

AAA closed a $57.4M funding round; Dompé Group participated in the latest round and now holds a 7.7% stake

BioMimetix Inc.

Unknown

7/22

$2

Omni Bio Pharmaceutical Inc., of Denver, picked up a 25% equity stake in recently formed BioMimetix

Cevec Pharmaceuticals GmbH

Cologne, Germany

7/26

€6 ($8.6)

Cevec raised $8.6M in a financing round led by NRW.BANK and Creathor Venture Fonds; the firm's current investors, a group of private and institutional investors and ERP Startfonds of KfW bank also participated

Coronado Biosciences Inc.

New York

7/7

$25.8

Coronado closed a $25.8M Series C round led by National Securities Corp.

Cytochroma Inc.

Markham, Ont.

7/27

$1

Cytochroma closed an equity investment from the Investment Accelerator Fund of Ontario

glcare Pharma Inc.

Montreal

7/22

$7

glcare raised $7M in a Series A round co-led by Forbion Capital Partners and Genesys Capital

Immune System Therapeutics Ltd.

Sydney, Australia

7/25

A$2.6 ($2.8)

Immune System raised $2.8M in a placement of 5.2M shares priced at A50 cents apiece

Novira Therapeutics Inc.

Radnor, Pa.

7/27

$2.5

Novira completed a second round of seed funding to bring its early financing total to about $2.5M; the financing was led by Delaware Crossing Investor Group, the Mid-Atlanta Angel Group Fund II and Robin Hood Ventures; existing investor BioAdvance also participated

Peloton Therapeutics Inc.

Dallas

7/28

$18

Peloton raised $18M in a Series A round led by The Column Group, with participation from Remeditex Ventures and Peter O'Donnell Jr.

Pharminox Ltd.

Nottingham, UK

7/8

£1.5 ($2.4)

Pharminox raised $2.4M from existing shareholders and new private investors

SARcode Bioscience Inc.

Brisbane, Calif.

7/18

$44

SARcode raised $44M in the Series B round led by Sofinnova Ventures; other investors were Rho Ventures, Alta Partners and Clarus Venture Partners

Sorbent Therapeutics Inc.

Sunnyvale, Calif.

7/5

$36

Sorbent expanded its Series B round by $36M, for a deal total of $53M; the round was led by Novartis Venture Funds, and was joined by Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem

SpringLeaf Therapeutics Inc.

Boston

7/11

$4

SpringLeaf secured an additional $4M in a second closing of its Series B round from new investor Excel Venture Management, bringing the total round to $19M

Tarsa Therapeutics Inc.

Philadelphia

7/13

$24.5

Tarsa raised $24.5M through a second round; investors were MVM Life Science Partners, Quaker BioVentures, Novo A/S and Unigene Laboratories Inc.

Vantia Therapeutics Ltd.

Southampton, UK

7/7

$6.5

Vantia raised $6.5M in a Series B financing; investors were Novo A/S, SV Life Sciences and MVM Life Science Partners

Verastem Inc.

Boston

7/15

$32

Verastem raised $32M in a Series B round led by Advanced Technology Ventures and Astellas Venture Management; other investors were Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital

Visionary Pharmaceuticals Inc.

San Diego

7/28

ND

Visionary raised undisclosed seed round investments from a consortium of angel investors

Zafgen Inc.

Cambridge, Mass.

7/7

$33

Zafgen raised $33M through Atlas Venture and Third Rock Ventures


Notes:

Currency conversions are based on exchange rates at the time of the deal.

** Denotes the date the item ran in BioWorld International.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

ND = Not disclosed.